Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FEM-PrEP: Truvada for HIV Prevention in Women
NCT00625404Phase 3Completed
- Sponsor
- FHI 360
- Start
- May 2009
- Primary completion
- Aug 2012
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in human immunodeficiency virus infection (HIV) comparing Truvada Arm with Placebo Arm (2 arms). Primary endpoints: Incidence of HIV Infection at 52 weeks, Confirmed Grade 2 or Higher Serum Creatinine Toxicity at 56 weeks and 4 more. Started May 2009; status: completed.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT00625404.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00625404.